Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
| Autor: | Sarah Harmand, Pascal Guillon, Xavier Ansolabehere |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Olanzapine
050101 languages & linguistics Perphenazine medicine.medical_specialty viruses 02 engineering and technology Persistence (computer science) Injections chemistry.chemical_compound Internal medicine Paliperidone Palmitate 0202 electrical engineering electronic engineering information engineering medicine Humans 0501 psychology and cognitive sciences Pharmacology (medical) Retrospective Studies Pharmacology Risperidone business.industry 05 social sciences Retrospective cohort study Discontinuation Zuclopenthixol chemistry Delayed-Action Preparations Schizophrenia Haloperidol 020201 artificial intelligence & image processing France business medicine.drug Antipsychotic Agents |
| Zdroj: | International journal of clinical pharmacology and therapeutics. 57(9) |
| ISSN: | 0946-1965 |
| Popis: | Objective Antipsychotics exhibit different profiles of efficacy and safety in patients with schizophrenia. It has recently been reported that the risk of rehospitalization was the lowest with paliperidone palmitate (PP), a long-acting injectable (LAI), when compared with other LAIs (of zuclopenthixol, perphenazine, and olanzapine). We aimed to investigate whether treating patients with PP was also associated with improved real-life treatment persistence. Materials and methods We conducted a retrospective observational study of the LAI antipsychotics (LAIAs) dispensed in French retail pharmacies. Treatment persistence was defined as the non-discontinuation of LAIAs for ≥ 5 months after LAIA initiation (and was also analyzed by Kaplan-Meier persistence curves). Results A total of 4,492 patients were included in the study. The persistence rate was significantly greater for LAI-PP (64.5%) than for either LAI haloperidol decanoate (HD) or LAI risperidone microspheres (R) (46.4% and 35.4%, respectively). Multivariate Cox analyses illustrated that LAIA initiation with HD or R significantly increased the risk of discontinuation when compared with PP. Conclusion PP demonstrated a significantly higher persistence rate than HD or R. Moreover, LAIA initiation with HD or R significantly increased the risk of treatment discontinuation relative to PP. Further comparative studies are required to comprehensively determine whether PP has a better efficacy and/or safety profile than other LAIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|